Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04858230
Other study ID # LymphoPilot
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 8, 2021
Est. completion date September 30, 2023

Study information

Verified date October 2023
Source Lymphatica Medtech SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study is a first-in-man, single arm, open-label, single center study to assess feasibility and safety of a novel implantable device, LymphoPilot, in patients suffering from secondary upper limb or lower lymphedema.


Description:

The study consists in a first-in-man clinical investigation for LymphoPilot, an investigational implantable medical device. LymphoPilot is composed of an implanted part and an external wearable device. The implanted part (pump, drainage catheter and output catheter), is implanted in the subcutaneous tissue of the arm or leg and drains excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The external part consists in a wearable controller used to activate the implanted pump. The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure. The device is activated in the postoperative room by placing the external wearable device on patient's limb, in proximity of the implanted pump. Patients are required to wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. Follow-up visits are planned 1, 4 and 8 weeks after device implantation. The implanted device is removed with a surgical procedure in local anesthesia 8 weeks after device implantation, and 2 additional follow-up visits are planned after device removal.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female patients, 18 years and older - Patients with unilateral secondary upper or lower limb lymphedema. Exclusion Criteria: - Active cellulitis/infection - Lymphedema associated with active cancer requiring chemotherapy or radiotherapy - Motor and sensitive neurological deficiency - Post-operative edema (i.e. acute edema following breast cancer related surgery) - Any contraindication to surgery or to loco-regional or general anesthesia - Patient participating in any other clinical study - Patient unable to provide informed consent - Patient with pacemaker - Pathologies associated with an overload of the cardiac system - Poor wound healing - Pregnancy or breastfeeding - Known intolerance to implantable devices - Known allergies to silicone - Patient needing magnetic therapy - Any other condition that according to the principal investigator makes the patient unsuitable for the participation in the trial - Patient refusing to receive information about incidental findings on her health status discovered during the clinical investigation - L-Dex score lower than 6.5 at screening

Study Design


Intervention

Device:
LymphoPilot
LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device. The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure. Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation.

Locations

Country Name City State
Switzerland Angiology Service - Centre Hospitalier Universitaire Vaudois (CHUV) Lausanne Vaud

Sponsors (1)

Lead Sponsor Collaborator
Lymphatica Medtech SA

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence, frequency and severity of device-related adverse events Occurrence, frequency and severity of device-related adverse events are used to evaluate device safety From enrollment until final visit, 4 weeks after device removal.
Secondary Device functionality evaluated via ultrasound imaging Ultrasound imaging is used to verify fluid flow in the implanted catheters At day 1 (implant surgery), day 7, day 28 and day 56
Secondary Limb volume Arm or leg volume evaluated by tape measure and by perometer At day 0 (baseline), day 7, day 28, day 56, day 66, day 84
Secondary L-Dex score L-Dex score is measured via bioimpedance spectroscopy At day 0 (baseline), day 7, day 28, day 56, day 66, day 84
Secondary Upper extremity function The Quick Disability of Arm, Shoulder, Hand Questionnaire (DASH) is used to evaluate upper extremity function At day 0 (baseline) and at day 56
Secondary Lower extremity function The Lower Extremity Functional Scale (LEFS) is used to evaluate lower extremity function At day 0 (baseline) and at day 56
Secondary Physical functioning evaluated via validated SF-36 questionnaire The Short Form-36 (SF-36) questionnaire is used to evaluate patient's physical functioning.
Scoring scale: 0 to 100%, where the highest percentage represents the best outcome.
At day 0 (baseline) and at day 56
Secondary Role limitations due to physical health evaluated via validated SF-36 questionnaire The Short Form-36 (SF-36) questionnaire is used to evaluate patient's role limitations due to physical health.
Scoring scale: 0 to 100%, where the highest percentage represents the best outcome.
At day 0 (baseline) and at day 56
Secondary Role limitations due to emotional problems evaluated via validated SF-36 questionnaire The Short Form-36 (SF-36) questionnaire is used to evaluate patient's role limitations due to emotional problems.
Scoring scale: 0 to 100%, where the highest percentage represents the best outcome.
At day 0 (baseline) and at day 56
Secondary Energy/fatigue evaluated via validated SF-36 questionnaire The Short Form-36 (SF-36) questionnaire is used to evaluate patient's energy/fatigue.
Scoring scale: 0 to 100%, where the highest percentage represents the best outcome.
At day 0 (baseline) and at day 56
Secondary Emotional well-being evaluated via validated SF-36 questionnaire The Short Form-36 (SF-36) questionnaire is used to evaluate patient's emotional well-being.
Scoring scale: 0 to 100%, where the highest percentage represents the best outcome.
At day 0 (baseline) and at day 56
Secondary Social functioning evaluated via validated SF-36 questionnaire The Short Form-36 (SF-36) questionnaire is used to evaluate patient's social functioning.
Scoring scale: 0 to 100%, where the highest percentage represents the best outcome.
At day 0 (baseline) and at day 56
Secondary Pain evaluated via validated SF-36 questionnaire The Short Form-36 (SF-36) questionnaire is used to evaluate patient's pain. Scoring scale: 0 to 100%, where the highest percentage represents the best outcome. At day 0 (baseline) and at day 56
Secondary General health evaluated via validated SF-36 questionnaire The Short Form-36 (SF-36) questionnaire is used to evaluate patient's general health.
Scoring scale: 0 to 100%, where the highest percentage represents the best outcome.
At day 0 (baseline) and at day 56
Secondary Quality of life evaluated via validated LYMQOL-leg questionnaire The Lymphedema Quality of Life Questionnaire for leg Lymphedema (LYMQOL-LEG) questionnaire is used to evaluate assessing problems in functioning in patients with lower limb lymphedema.
Scoring scale: 0-10, where highest scores represent the best outcome.
At day 7 and at day 56
Secondary Quality of life evaluated via validated LYMPH-ICF-UL questionnaire The Lymphedema Functioning, Disability and Health Questionnaire for Upper Limb Lymphedema (LYMPH-ICF-UL) questionnaire is used to evaluate assessing problems in functioning in patients with upper limb lymphedema.
Scoring scale: 0-100, where highest scores mean a worse outcome.
At day 7 and at day 56
Secondary Ease of use of the device Device usability evaluated via dedicated survey At day 7 and at day 56
See also
  Status Clinical Trial Phase
Completed NCT04575636 - MRL in the Upper Extremity N/A
Completed NCT03252145 - Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device N/A
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A
Completed NCT05754346 - Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema N/A
Not yet recruiting NCT06264817 - Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema. N/A
Completed NCT06399458 - The Relationship Between Primary Lymphedema and Joint Hypermobility
Recruiting NCT06302361 - Lymphovenous Anastomosis for Breast Cancer Lymphedema N/A
Active, not recruiting NCT06278298 - Different Level of ECSWT in Post Mastectomy Lymphedema N/A
Completed NCT05037708 - Effects of Physiotherapy in the Treatment of Lymphedema After Breast Cancer N/A
Not yet recruiting NCT02453295 - Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema N/A
Completed NCT05660590 - Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema N/A
Withdrawn NCT02458391 - Complete Decongestive Therapy in Breast Cancer-Related Lymphedema N/A
Completed NCT04766489 - Evaluation of the Treatment Response in Breast Cancer Related Lymphedema N/A
Enrolling by invitation NCT04165512 - Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema N/A
Recruiting NCT05762224 - Comparative Effects of KT and PG on UE Lymphedema and Functional Disability After Mastectomy N/A
Recruiting NCT06082349 - The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema N/A
Recruiting NCT05142800 - Screening For BCRL In Targeted Therapy For Breast Cancer
Recruiting NCT06012786 - Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
Not yet recruiting NCT06113627 - Lymphatic Response to Resistance Exercise in Breast Cancer Survivors N/A
Completed NCT06036173 - Body Awareness and Functionality in Lymphedema